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Caregivers’ perspectives and experiences of
withdrawing acetylcholinesterase inhibitors
and memantine in advanced dementia: a
qualitative analysis of an online discussion
forum
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Abstract
Background: There is considerable uncertainty surrounding the medications used to delay the progression of
dementia, especially their long-term efficacy and when to withdraw treatment with these agents. Current research regarding
the optimal use of antidementia medication is limited, contributing to variability in practice guidelines and in
clinicians’ prescribing practices. Little is currently known about the experiences encountered by caregivers of
people with dementia after antidementia medication is withdrawn.
Aim: To investigate the experiences and perspectives of carers and family members when antidementia medications
(cholinesterase inhibitors and/or memantine) are stopped, by analysing archived threads and posts of an online
discussion forum for people affected by dementia.
Methods: Archived discussions from Talking Point, an online discussion forum hosted by the Alzheimer’s Society
UK, were searched for threads discussing antidementia medication withdrawal and relevant threads were
analysed thematically using the Framework method. Participant demographics were not established due to
usernames which ensured anonymity.
Results: Four key themes emerged: (1) expectations about withdrawal, (2) method of withdrawal, (3) clinical
condition on withdrawal, and (4) the effect of withdrawal on caregivers.
Conclusions: Online discussion forums such as Talking Point provide dementia carers with an outlet to seek
help, offer advice and share experiences with other members. The study findings highlight the complexity surrounding
optimising dementia pharmacotherapy and antidementia medication withdrawal, highlighting the need for treatment
to be person-centred and highly individualised.
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Background
Dementia is a progressive, chronic, neurodegenerative
condition characterised by widespread neuronal cell
death which results in multiple cognitive deficits across
a range of domains including memory, behaviour, lan-
guage, movement and executive function, and ability to
recognise familiar people and objects [1, 2]. Dementia is
an increasingly challenging global public health concern;
it has been estimated that 46.8 million people were liv-
ing with dementia in 2015 and that this will rise to 74.7
million in 2030 and 131.5 million by 2050, due to chan-
ging demographics and increasing life expectancy [3].
Current medications approved for dementia treatment
alleviate associated symptoms and delay disease progres-
sion but do not provide a cure [4, 5]. The cholinesterase
inhibitors (ChEIs), donepezil, rivastigmine and galanta-
mine, are the pharmacological agents of choice for the
treatment of mild to moderate Alzheimer’s disease [6],
and rivastigmine is licensed for Parkinson’s Disease De-
mentia (PDD) [7]. These agents are also frequently pre-
scribed off-label for use in other types of dementia, for
example, vascular dementia [5]. Loss of cholinergic neu-
rons is apparent in the pathophysiology of Alzheimer’s
disease and ChEIs exert their therapeutic effect by inhi-
biting acetylcholinesterase at synaptic clefts [5, 8]. This
increases the availability of acetylcholine to interact with
postsynaptic acetylcholine receptors, enhancing cholin-
ergic transmission [5]. Memantine is a non-competitive
N-methyl-D-aspartate (NMDA) receptor antagonist li-
censed for use in moderate to severe Alzheimer’s disease
[5, 6]. Its mechanism of action is currently unknown,
but it is thought to regulate glutamate activity, prevent-
ing overstimulation of glutamate receptors whilst not af-
fecting glutamate transmission needed for normal
physiological function [5, 8].
As dementia progresses, cognitive and physical decline
can adversely impact on the ability of people with demen-
tia to conduct basic and instrumental activities of daily liv-
ing, often leaving them dependent on others for care [2,
9–11]. Caregivers of people with dementia are often pre-
sented with challenging and complex needs, higher levels
of dependency and morbidity in the more severe stages of
the condition [2, 12, 13]. People with advanced dementia
often cannot participate in decision-making about their
care; consequently decisions often have to be made by
their caregivers (family members, friends and next of kin)
[14–20]. Making decisions on behalf of a person with de-
mentia can be difficult and complex [20], and a source of
burden and stress for these carers, who are at increased
risk of developing mental health disorders, particularly de-
pression and anxiety [21, 22]. Recent work has shown that
caregivers may find the decision-making process around
medication withdrawal extremely difficult [23]. This re-
flects the current uncertainty in the literature regarding
the long-term efficacy of antidementia drugs and when to
stop treatment due to the lack of high-quality randomised
controlled trials of ChEI and memantine discontinuation,
and the consequent variability in clinician decision-mak-
ing and prescribing practices with respect to antidementia
drugs [8, 24–28].
This study aimed to investigate the experiences and per-
spectives of carers and family members when antidemen-
tia medications (ChEIs and/or memantine) are stopped,
by analysing archived discussions of Talking Point, a
UK-based online discussion forum where anyone affected
by dementia, including patients, carers, family members
or friends, can receive support. This manuscript presents
significant further analysis and discussion of preliminary
findings presented previously [29].
Methods
Setting
Talking Point is a fully public online discussion site
hosted by Alzheimer’s Society UK. It contains various
categories (broad subject areas), which themselves con-
tain forums (more specific subject areas for discussion
on different topics to assist members in finding, for
example, people who are in a similar situation or at a
similar stage of dementia). These forums in turn con-
tain threads. A thread is a collection of posts defined by
a title containing an opening or original post which
opens the dialogue of discussion. It can contain any
number of posts, including multiple posts from the
same members, even if they are one after the other. A
post is a message enclosed into a block containing the
user’s details and the date and time it was submitted.
Members are permitted to edit or delete their own
posts. At the time of data collection (14th April 2017),
Talking Point statistics showed that there were 94,283
threads, 1,382,996 posts, 54,531 members and 844 ac-
tive members.
Only individuals who have registered as members are
able to post new threads or edit posts, reply to other
members’ threads, edit posts, receive email notification of
replies to posts and threads, and send private messages to
other members. However, as a fully public online discus-
sion site, threads and posts on Talking Point are visible to
“non-member” visitors to the forum. Archived discussions
are also accessible to non-member visitors without any re-
quirement to register or “log on” to the website.
The researcher (SG) searched the forum and collected
the data as a guest; member registration was not under-
taken. This ensured that the degree of intrusiveness of
the research was minimal; the researcher was not ac-
tively involved in online discussions either as a declared
researcher or a covert participant. Additional personal
data from Talking Point members were not solicited for
the purposes of this research. Informed consent was not
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sought from the authors of the sampled posts; the Eco-
nomic and Social Research Council (ESRC) Framework
for Research Ethics [30] considers forums or spaces on
the internet and web “that are intentionally public” may
be considered “in the public domain”.
This study is reported according to the Standards
for Reporting Qualitative Research (SRQR) recom-
mendations [31].
Procedure
Talking Point provides a standard search feature as well
as an advanced search option which enables users to de-
fine specific information required to refine results
returned. For the purposes of this study, threads dating
from the inception of the Talking Point forum in 2005
through to February 2017 were searched by inserting
keywords into the advanced search facility. Search terms
were discussed and agreed by the authors (CP and SG).
The following terms, and combinations thereof, were
used: ‘cholinesterase inhibitor(s)’, ‘acetylcholinesterase in-
hibitor(s)’, ‘donepezil’, ‘rivastigmine’, ‘galantamine’, ‘meman-
tine’, ‘NMDA antagonist’, ‘withdraw*’, ‘discontinu*’, ‘remov*’
‘cessat*’, ‘stop*’, ‘held’, ‘deprescribing’, ‘drug holiday’, ‘ad-
vanced dementia’, ‘dementia’, ‘drug withdrawal’, ‘medica-
tion withdrawal’, ‘drug guidance’. Relevant threads and
posts were copied into a Microsoft Word document and
analysed thematically using the Framework method [32].
This analytical method sits within a broad family of
methods often termed thematic analysis or qualitative
content analysis, and is becoming an increasingly popu-
lar analytical method in healthcare research [33].
The defining feature of the Framework Method is the
matrix output of rows (cases), columns (codes) and ‘cells’
of summarised data, providing a structure whereby the
researcher can systematically reduce the data in order to
analyse it by case and code [33]. While in-depth analyses
of key themes can take place across the entire data set,
the views of each respondent remain connected to other
aspects of their account within the matrix so that the
context of the individual’s views is retained. Comparing
and contrasting data across cases as well as within indi-
vidual cases is a key feature of the Framework method
[34]. The researcher is able to explore data in depth
while simultaneously maintaining an effective and trans-
parent audit trail, thus enhancing the rigour of the ana-
lytical process and the credibility of the findings [35].
Framework analysis is often overseen by an experienced
qualitative researcher, but inexperienced researchers and
those new to qualitative research may contribute to the
analysis [34].
In this study, the five-stage method of analysis developed
by Ritchie and Spencer [32] was adopted; the researcher
(SG; a female undergraduate pharmacy student) re-read
each transcript several times to ensure familiarisation with
the data (Stage 1). At this stage, irrelevant data from
the initial extraction were discarded. Data were anno-
tated with descriptive codes; for example, clinical con-
dition on medication withdrawal, effect on withdrawal
on carers. In Stage 2, core themes were identified from
the descriptive codes, reviewed and refined on discussion
with the first author (CP) to produce the final coding
framework. The transcripts were then read again and po-
tentially relevant text highlighted and coded in the mar-
gins (Stage 3). In Stage 4, highlighted text from posts were
electronically copied and pasted into a Microsoft Word
file according to the core themes. During this process, pat-
terns within themes emerged, resulting in the production
of sub-themes (for example, improvement in clinical con-
dition on medication withdrawal, decline in clinical condi-
tion on withdrawal, complex or uncertain change in
clinical condition on withdrawal). In Stage 5, findings were
synthesised by combining patterns of data, mapping out
connections and developing an overall structure. These in-
terpretations were supported by illustrative verbatim quo-
tations from the data set. Validation of analysis was
performed by SG and CP (a female academic pharmacist
with experience in qualitative research).
Although Talking Point recommends that members
use nicknames or create usernames which ensure ano-
nymity, all usernames were changed using a computer-
generated program to produce a random list of first
names, thereby providing further assurance of anonym-
ity in presenting the study findings using illustrative
verbatim quotations.
Ethics and governance
Ethical approval was granted by the Research Ethics
Committee of the School of Pharmacy, Queen’s Univer-
sity Belfast (Ref: 012PMY2017). Permission to search
and analyse the threads and posts from the Talking Point
forum was granted by the web editors of the forum, Alz-
heimer’s Society, UK.
Results
The search of the forum yielded 95 threads comprising
posts from 112 users which spanned the full date range of
forum activity and contained relevant information regard-
ing the withdrawal of antidementia medication. Thematic
analysis revealed four key themes: (1) the opinion of
others, (2) method of withdrawal, (3) clinical condition on
withdrawal and (4) the effect of withdrawal on caregivers.
Expectations about withdrawal
Talking Point users who expressed opinions regarding the
withdrawal of antidementia medications had not always
experienced these situations first hand, but often based
their expectations on advice from others. Forum partici-
pants were keen to impart knowledge they had gained
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from these individuals including healthcare professionals,
family, friends or other Talking Point members. The most
common vicarious experience voiced within this theme
was a rapid decline following medication withdrawal:
“…the consultant told me that once the mementine
[sic] stopped working it would be like falling of [sic] a
cliff regarding his symptoms and there was nothing
then that would help........they were right.” (Anne).
Others suggested that a gradual decline post withdrawal
may be expected:
“Stopped Memantine... and [healthcare professional]
said to expect a gradual peaceful withdrawal from the
world that could take months.” (Frederick).
In addition, some members reported that they were ad-
vised that an irreversible decline may occur when antide-
mentia medication was removed:
“He told us not to take her off because she would drop
like a rock and once they go down, they stay down and
he can’t get them back up.” (Vicky).
Method of withdrawal
The way in which these drugs were withdrawn pro-
duced concern amongst carers. Members described sit-
uations where they felt the manner of drug withdrawal
affected the patient’s condition, rather than the actual
withdrawal itself. Two dominant methods became ap-
parent throughout the forum; weaning and immediate
withdrawal. Many members expressed distress at the
perceived consequences of rapid cessation, which in-
cluded deterioration in patient condition and distress:
“I am devastated that my dad’s medication
(galantamine) was stopped suddenly by a new
consultant when he started to deteriorate, in favour
of memantine. I think the sudden change almost
certainly added to his deterioration and his
distress.” (Alice).
Others reported increased aggression upon medication
withdrawal:
“He has never before hurt anyone and we feel it was
not his fault, as it was due to drug withdrawal. The
consultant was very angry as he said these drugs
should never be stopped suddenly.” (Agnes).
In addition to emergence of neuropsychiatric symp-
toms, physical withdrawal symptoms were also observed:
“…did stop the drug this week and Dad had severe
withdrawal symptoms including shaking, convulsing,
jerking, twitching, hallucinating, and was unable to
sleep for 18 hours.. . I am horrified he was put through
this and cannot understand why it was withdrawn
totally.... instead of him being slowly weaned off it”.
(Kate).
Conversely, a small number of members reported
positive experiences with immediate withdrawal of anti-
dementia medications.
..they told me to stop giving it immediately. Physically
he is so much better and not so tired and breathless.
(Evelyn).
... I stopped all his meds and he recovered in a matter
of days…(Alison).
Clinical condition on withdrawal
Within this theme, carers reported that medication with-
drawal impacted on the clinical condition of the patient
in a range of different ways, as detailed below.
No clinical change on withdrawal
Many carers reported no difference in patient condition
following antidementia medication cessation in compari-
son to during treatment:
“We stopped MIL [mother-in-law]’s donepezil and
found no difference.” (Angela).
“…to be honest I don’t think that stopping the Ebixa
[memantine] has had any noticeable effect.” (Linda)
Improvement in clinical condition on withdrawal
Many carers witnessed an improvement in patients’ clin-
ical condition following drug cessation. These improve-
ments ranged from amelioration in behavioural and
psychological symptoms of dementia (BPSD), physical
condition and functional status, to elimination of antide-
mentia medication side-effects, or an overall impression
of improved condition. Improvements in BPSD were ob-
served across domains including mood, aggression, anx-
iety, agitation and communication:
“She has much improved since then. She can talk now
and makes sense most of the time.…… I feel I have got
my wife back.” (Michael).
Carers did not always describe the side-effects from anti-
dementia medications experienced by patients, however
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they did discuss elimination of these side-effects when
withdrawal occurred:“…very bad side effects…he came off
them and the side effects disappeared.” (Loretta).
Improvements in drinking, eating and overall movement
were also observed by some carers:
“All her meds were withdrawn and she was expected
to slowly withdraw and pass away. Mum defied all
the expectations, started eating and drinking a little
more and gradually improved. She is now stable,
albeit at end stages… For her I think the withdrawal
of the meds has had a remarkable effect..” (Olivia).
Carers did not always specify which aspects of a patient’s
condition had improved or in some cases described a gen-
eral overall improvement:
“…but the best day of my life was when she stopped
taking it... We’re now able to lead a normal life again.
I think she’s better of [sic] without it.” (Robin).
Decline in clinical condition on withdrawal
Many carers reported a worsening in the condition of
the patient following antidementia drug removal. Deteri-
oration was seen in behavioural and psychological symp-
toms, physical condition and functional status, or a
general worsening in condition. Deterioriation in behav-
ioural and psychological symptoms observed included
confusion, a worsening of communication, low mood,
and worsened aggression, agitation and anxiety:
“My mum was taken off Aricept [donepezil] and
deteriorated rapidly…her talking ability started to
deteriorate, she lost a lot of her cognitive skills.
Basically went downhill fast….” (Christine).
Deterioration was reported in two cases following
switching from a branded formulation of donepezil to a
generic version or from one generic version to another:
“He was given a different brand of the donepezil once
and I noticed a deterioration in his behaviour.” (Janet).
“..now on a generic Donepezil….. decline in a matter of
a few weeks…. and more aggressive”. (Mary).
As many carers were uncertain about drug efficacy, some
chose to use drug holidays (the intentional interruption of
pharmacological treatment for a defined period with a spe-
cific clinical purpose [36]) to test medication efficacy and
withdrawal effects on individuals affected by dementia:
“…we used that period as a [sic] opportunity to see
how a ‘drug holiday’ worked for my wife and, because
of the deterioration I saw, our consultant was happy to
continue prescribing Aricept on the grounds that
ceasing the drug would have a major effect on our
daily living.” (Derek).
Carers did not always specify what aspects of patient
condition declined after withdrawal. Some carers, like
Tina, observed an overall decline:
“... the results have been more scary than I could
have imagined: my husband is almost unable to
understand what is being said to him, or follow
instructions, he is mostly unable to communicate,
he is completely unable to take care of himself,
struggles climbing stairs, unable to get into a car
(therefore now housebound!), almost completely
incontinent…” (Tina).
These perceived negative consequences of antidemen-
tia drug withdrawal were distressing for both patients
and carers, and in some cases, this resulted in the drug
being restarted or, in the case of ChEIs, in memantine
being prescribed.
“it became immediately clear that the medication
had been giving her a quality of life that was
valuable. Without it, her cognitive functioning and
her ability to communicate was even worse, which
was even more frustrating for her. We restarted it
within a fortnight and she returned to her previous
level.” (Rebecca).
“Aricept [donepezil] was withdrawn… Within a
week we witnessed the most incredible decline…It
was a nightmare, and I felt I needed to do
something…We started on a very low dose of Ebixa
[memantine]” (Alistair).
Complex or uncertain change in clinical condition on
withdrawal
Analysis revealed that antidementia medication with-
drawal affected individuals differently. Numerous carers
stated that after withdrawal, one aspect of the patient’s
clinical condition improved, whilst another declined:
“She has nosedived, dementia wise, since stopping
them but is happier & feeling better & easier for me to
manage.” (Rod).
“…they were stopped. She now is more dopey and has
lost some of her verbal skills but seems more aware of
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what is happening and is loads calmer. It makes me
wonder if the drugs were a good thing.” (Fred).
Some carers were reluctant to apportion blame to
medication withdrawal for the change in patient condi-
tion, and suggested that there were other factors that
could have attributed to the deterioration in condition
or to development of symptoms:
“To me he is worse, always worse. In the past
month he has declined, but I cannot say if this is
due to him not taking his medication, or the Exelon
[rivastigmine] being stopped, or him going into
hospital, or having new medication to stop his
aggressiveness.” (Hannah).
In many instances, carers expressed confusion and
indecision as to whether drug withdrawal caused pa-
tient decline or whether it was the natural course of
disease progression:
“Within a couple of weeks mum had deteriorated
dreadfully but of course I have no way of telling
whether that was as a result of the withdrawal of the
medication or just coincidence.” (Caroline).
Effect of withdrawal on caregivers
Making decisions about loved ones’ medications, includ-
ing withdrawal, was highly emotive and a source of
worry and stress for many carers, who expressed fear for
what the future held:
“I fear we are on the slippery slope to nowhere, and I
am dreading the future more than ever before.” (John).
“ I was really worried that I was being asked to
oversee all these changes. With no medical training,
I was made responsible for the gradual withdrawal
or introduction of a large number of pretty heavy
drugs, and I was really worried that I might make
a mistake or miss some potentially dangerous side
effect” (Joan).
Carers expressed feelings of guilt, uncertainty over
whether they were making the right decision, and lack of
support from healthcare professionals:
“This makes me feel awful. That we shouldn’t have
asked that the medication be stopped”. (Beryl).
“‘Fobbed off ’ is exactly how I felt when the consultant
phoned me with his cold and clinical decision to take
my husband off Aricept” (Barbara).
Conversely, some carers described a sense of comfort
or relief that they had made the decision to stop antide-
mentia medication:
“she was just like her old self, calm, no confusion,
no anxiety and I thought a little miracle had
happened.” (Sam).
“I would like to say that I am happier with the
situation but really I am not because she is just so
so sad. I am glad however they have removed the
drug….” (Richard).
Discussion
Online discussion forums are increasingly being recog-
nised as an important source of support and information
available to hard-to-reach groups such as carers of people
with dementia who do not access support services or as a
complement to other support services offered [37]. They
have been employed as a source of “naturally occurring”
data in a number of clinical areas [38–45] including de-
mentia and palliative care [37, 46, 47]. To the best of the
authors’ knowledge, this is the first study to analyse the
content of an online discussion forum for people affected
by dementia, to provide insight into the concerns and
views of caregivers specifically regarding withdrawal of
antidementia medications.
Thematic analysis of the threads and posts on the sub-
ject of antidementia medication withdrawal highlighted
this as a highly emotive and widely deliberated issue for
caregivers, with posts spanning more than a decade, thus
illustrating that it has been and continues to be a source
of concern.
The evidence base to guide discontinuation of antide-
mentia medications is limited; no blinded RCTs of dis-
continuation versus continuation of memantine have
been conducted to date [28]. Systematic reviews and
meta-analyses of ChEI discontinuation [27, 28] suggest
a clinically significant worsening in cognitive symptoms
after ChEI discontinuation, and a possible worsening in
neuropsychiatric symptoms. Although the quality of
evidence has been assessed as low due to risk of bias,
lack of generalisability and indirectness of the included
studies [28], this is reflected in the current study in the
caregivers’ reports of healthcare professionals’, family
members’, friends’ or other Talking Point forum mem-
bers’ previous experiences of antidementia medication
withdrawal.
The manner in which antidementia medications were
withdrawn was highlighted as a source of concern for
caregivers in the current study. There is evidence to sug-
gest that a gradual downwards titration in dose may be
clinically appropriate [8, 24, 27, 48, 49], with reports of
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adverse effects or discontinuation syndrome if medica-
tions are withdrawn abruptly [28, 50–55]. This is reflected
in the caregivers’ descriptions of negative consequences
for patients when antidementia medications were sud-
denly withdrawn.
Due to limited numbers and quality of trials to guide
treatment recommendations, there is considerable clin-
ical uncertainty regarding use of antidementia medica-
tions in the more severe stages of dementia, and how
and when they should be discontinued [8, 24–28, 56–
58]. Further, these trials often did not include people
with advanced/end-stage dementia [28]. This clinical un-
certainty is reinforced by the range of differing experi-
ences of medication withdrawal reported by the caregivers
in the current study. Some reported no observable differ-
ence in patient condition after antidementia medication
cessation. Others, though notably fewer in number, re-
ported an improvement in terms of elimination of side-ef-
fects associated with the antidementia medication or
improved communication, eating and drinking or move-
ment. The majority of caregivers, however, described a de-
cline in the clinical condition of the patient, in relation to
BPSD, physical condition, functional status or an over-
all general decline. In some cases, the extent and con-
sequences of decline associated with antidementia
medication withdrawal resulted in reinstatement of
previous ChEI treatment or, if physicians felt the de-
mentia had progressed, prescription of memantine.
This is reflected in the literature in the area and in
clinical and treatment guidelines [28, 59]. The diffi-
culty in quantifying the ongoing benefit of antidemen-
tia medications in people with dementia is well
recognised and it has been suggested that a trial with-
drawal is useful in identifying patients who are still
benefiting from the medication [60].
In this study, caregivers reported that attempting a
drug holiday resulted in decline in the clinical condi-
tion of the patient, a finding similar to the open-label,
industry-sponsored study by Doody et al., in which
temporary drug cessation was reported to have a detri-
mental effect on cognition that was not fully recovered
when the medication was re-initiated [61]. Caregivers also
reported clinical decline if medication was switched from
one branded drug to another or to a generic counterpart.
Previous work has highlighted the possibility of clinical
deterioration for people with mild-to-moderate dementia
when switching ChEIs [62], but did not consider the ad-
vanced/end of life stages. However, the study finding of a
difference on switching from a branded ChEI to a generic
version has not been reported in the literature, and con-
trasts with work reporting no significant difference be-
tween generic and branded donepezil on quality of life of
patients with Alzheimer’s disease [63]. This finding sug-
gests further exploration of the effects of switching
between generic and branded antidementia drugs on the
clinical condition of patients in the advanced stages of de-
mentia is warranted.
Improvement in some aspects of the patient condition
accompanied by deterioration in other areas (a complex
change in the patient’s clinical condition) was described
by a number of caregivers in the current study. Current
clinical guidelines do not allow for a complex change in
patient condition, but do recognise that it can be diffi-
cult to determine whether there is ongoing benefit from
a medication due to the progressive and fluctuating na-
ture of dementia [28, 64, 65]. Previous work suggested
that caregivers and proxy decision-makers of people
with dementia are uncertain about benefits of antide-
mentia medications as there is no way to measure their
effects objectively, but these medications provided a
sense of hope [23, 66–71]. Carers in this study echoed
this, reporting that they were often unsure if decline was
a result of antidementia drug withdrawal or if it was part
of the natural progression of the disease.
The final key theme emerging in this study was the bur-
den, worry, stress and guilt caregivers experienced when
making decisions about loved ones’ medications. This re-
flects the literature in the area of decision-making on be-
half of people with dementia; making these decisions is
recognised to be a complex and difficult process [20], and
the emotional burden involved in the responsibility of
making decisions about medications has been acknowl-
edged [66, 72–76], as has the guilt and self-remonstration
experienced by those who feel that their decision has had
a detrimental impact on their loved one [72].
Strengths of the study
The Talking Point online discussion forum provided a
large data source for this study. The data collected and
analysed demonstrated a wide range of different types of
interactions between Talking Point members, ranging
from sympathetic and supportive to dissenting and chal-
lenging. User anonymity allowed members to be open in
sharing their feelings and experiences, minimising the
risk of social desirability bias.
Limitations of the study
Data were collected from one online discussion forum
hosted by the Alzheimer’s Society UK. These were therefore
restricted to carers who had internet access, were aware of
the facilities offered by Talking Point and could communi-
cate in the English language. Demographics of carers who
posted on the website were not available, and assumptions
cannot be made on generalisability or transferability of the
results to the wider population. Further, due to the nature
of data collection, it was not possible to clarify meanings or
obtain further explanation of posts. Carers’ interpretation
of effects of withdrawal were individualised and subjective;
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for example, what one carer described as a major deterior-
ation in patient condition may not have been ascribed the
same severity by another. In addition, any threads which
did not contain correct drug spelling on at least one occa-
sion, or which solely used brand names rather than generic
nomenclature for the ChEIs and memantine, were omitted
by the search thus potentially omitting relevant data. How-
ever, posts including brand names and misspelt drug names
were identified through searching using the other keywords
referring to stopping, withdrawing or withholding medica-
tions, which provides some reassurance that missing data
are limited.
Conclusion
This study is the first to explore caregivers’ views and
experiences of withdrawing antidementia medication in
people with advanced/end-stage dementia by analysing
the content of an online discussion forum for people af-
fected by dementia. It highlights the widely varying re-
sponse to treatment with antidementia medication and to
subsequent medication withdrawal experienced by people
with dementia, confirming the importance of a highly
individualised and person-centred approach in clinicians’
and caregivers’ decisions regarding the withdrawal of anti-
dementia medications.
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